SCHEMBL4082178

SCHEMBL4082178

COC(=O)COc1cccc(CNNC(=O)OC(C)(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
CACNA1B Q00975 1/20 0.41
GAA P10253 2/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
FFAR1 O14842 1/20 0.40
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7325159 0.86 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1CACNA1BHTT
SCHEMBL29800530 0.83 CA12 (0.48) KMT2AMEN1GAAPPARANPC1
SCHEMBL4087321 0.83 SLC7A5 (0.47) ALDH1A1CACNA1BGAASMN1; SMN2
SCHEMBL7394476 0.79 CYP1A2 (0.46) CYP1A2CYP3A4KMT2AMEN1GAA
SCHEMBL14987498 0.79 SLC7A5 (0.45) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7335575 0.78 POLB (0.46) ALDH1A1KMT2AGAAHTTMMP13
SCHEMBL24674845 0.78 PPARA (0.56) CYP3A4CYP2C9PPARGPPARASMN1; SMN2
SCHEMBL3811841 0.77 ACE (0.57) CACNA1BPPARGPPARA
SCHEMBL3811846 0.77 ACE (0.57) CACNA1BPPARGPPARA
SCHEMBL22396676 0.77 PPARA (0.45) CYP2C9CYP2C19CACNA1BGAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847533-B1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-14 EP disclosed
US-7531533-B2 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-05-12 US disclosed
EP-1847533-A1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF Asahi Kasei Pharma Corporation (JP) 2007-10-24 EP disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060590-A1 6-Membered heterocyclic compound and use thereof WNT1, CYP11B2, CYP11B1 ALDH1A1 1638/4885CYP1A2 615/4885CYP3A4 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.